

1617
Qhw

DOCKET NO.: QUIG-1002US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In application of: **Richard Rosenbloom**

Serial No.: **09/847,121**

Group Art Unit: **1617**

Filed: **May 2, 2001**

Examiner: **Mojdeh Bahar**

For: **COMPOSITIONS AND METHODS FOR THE TREATMENT
OF DIABETIC NEUROPATHY**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**RESUBMISSION OF REFERENCES PREVIOUSLY SUBMITTED IN AN
INFORMATION DISCLOSURE STATEMENT**

^{PT & TRADE}
This paper is filed for the purpose of resubmitting 55 references that were previously submitted in an Information Disclosure Statement filed concurrently with a Request for Continued Examination, for the purpose of having these references considered by the Examiner and having the Examiner initial the substitute forms PTO-1449 indicating that these references have been considered.

CERTIFICATE OF MAILING 37 CFR 1.8

I hereby certify that this document along with any document referred to as being attached or enclosed, is being deposited with the United States Postal services as first class mail, on **6 October 2004**, postage prepaid, in an envelope addressed to the Commissioner for Patents, Mail Stop Amendment, P.O. Box 1450, Alexandria, VA 22313-1450.

EDNA SCHMITTNER
Name of Person Signing Paper

Edna Schmittner
Signature of Person Signing Paper

DOCKET NO.: QUIG-1002US


PATENT

More specifically, the Examiner attached two sheets of substitute forms PTO-1449 to the Office Action dated September 28, 2004, copies of which are attached hereto, indicating in handwriting on the substitute forms PTO-1449 that, "no copy of the following document[s] have been received by office." The documents listed in the substitute forms PTO-1449 were identified as item nos. 1OD-55OD.

Documents 1OD-55OD were, in fact, received at the U.S. Patent and Trademark Office ("USPTO") on April 19, 2004, as evidenced by the copy of the date-stamped return receipt postcard indicating that these documents were received, which is attached hereto.

Accordingly, in view of the foregoing, consideration of the 55 references, without payment of an additional fee, is requested. In addition, the Examiner is requested to initial and return the substitute forms PTO-1449 to the applicant. For this purpose, fresh copies of the substitute forms PTO-1449 are enclosed herewith.


Respectfully submitted,



Kevin J. Dunleavy

Registration No. 32,024

Date: October 6, 2004
KNOBLE, YOSHIDA & DUNLEAVY, LLC
(Customer No.: 21302)
Eight Penn Center- Suite 1350
1628 John F. Kennedy Boulevard
Philadelphia, PA 19103
(215) 599-0600



*no copy of the following documents
have been received by office*

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	1OD	Cunningham JJ, "The glucose/insulin system and vitamin C: implications in insulin-dependent diabetes mellitus", <u>J Am Coll Nutr</u> 1998 Apr;17(2):105-8 Abstract
	2OD	Crabbe MJ, et al., "Aldose reductase: a window to the treatment of diabetic complications?", <u>Prog Retin Eye Res</u> 1998 Jul;17(3):313-83 Abstract
	3OD	Fujita T, et al., "Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships", <u>Chem Pharm Bull (Tokyo)</u> 1995 Jun;43(6):920-6 Abstract
	4OD	Guillausseau PJ, Preventive treatment of diabetic microrangiopathy: blocking the pathogenic mechanisms", <u>Diabete Metab</u> , 1994;20(2 Pt 2):219-28 Abstract
	5OD	McAuliffe AV et al., "Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion" <u>Nephron</u> 1998 Nov;80(3):277-84 Abstract
	6OD	Eaton RP, et al., "A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes", <u>J Diabetes Complications</u> 1998 Jan-Feb;12(1):34-8 Abstract
	7OD	Rastelli G, et al. "Structural bases for the inhibition of aldose reductase by phenolic compounds", <u>Bioorg Med Chem</u> , 2000 May;8(5):1151-8 Abstract
	8OD	Costantino L, et al., "Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches" <u>Med Res Rev</u> , 1999 Jan;19(1):3-23 Abstract
	9OD	Hosotani H, et al., "Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats" <u>Curr Eye Res</u> 1996 Oct;15(10):1005-7 Abstract
	10OD	Haraguchi H et al., "Inhibition of aldose reductase by dihydroflavonols in Engelhardtia chrysolepis and effects on other enzymes", <u>Experimentia</u> , 1996 June 15;52 (6) 564-7 Abstract
	11OD	Ohguro N, et al., "Topical Aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients" <u>Br J Ophthalmol</u> , 1995 Dec;79(12):1074-7 Abstract
	12OD	Benstead TJ, et al., "Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition", <u>Can J Neurol Sci</u> 1995 Aug;22(3):192-7 Abstract
	13OD	Okada Y, et al., "Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation" <u>Chem Pharm Bull (Tokyo)</u> 1995 Aug;43(8):1385-7 Abstract
	14OD	Costantino L, et al., "1-Benzopyran-4-one antioxidants as aldose reductase inhibitors", <u>J Med Chem</u> 1999 Jun 3;42(11):1881-93 Abstract
	15OD	Nishimura-Yabe C, "Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications" <u>Nippon Yakurigaku Zasshi</u> 1998 Mar;111(3):137-45 Abstract
	16OD	Tomlinson DR, et al., "Aldose reductase inhibitors and their potential for the treatment of diabetic complications" <u>Trends Pharmacol Sci</u> 1994 Aug;15(8):293-7 Abstract
	17OD	Airey M, et al., "Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy", <u>Cochrane Database Syst Rev</u> 2000;(2):CD002182 Abstract
	18OD	Maxwell SR, et al., "Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus", <u>Eur J Clin Invest</u> 1997 Jun;27(6):484-90 Abstract
	19OD	Himmerich S, et al., "Effect of Vitamins E and C on Nitric Oxide Production in Oxidized Low Density Lipoprotein Treated Human Aortic Endothelial Cells", <u>Academic Press</u> ; 2000, internet download at http://www.academicpress.com/www/journal/niox/9204.html
	20OD	Asahi K, et al., "Nitric Oxide Inhibits the Formation of Advanced Glycation End Products", <u>Kidney Int</u> 2000 Oct;58(4):1780-7

BEST AVAILABLE COPY

EXAMINER:

S. V. D.

DATE CONSIDERED:

9/15/04



FORM PTO-1449 Modified
List of Patents and Publications Cited by Applicant
Patent Trademark Office

documents have not been received

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	21OD	McCarty MF, "Nitric oxide deficiency, leukocyte activation and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - - preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline" <u>Med Hypotheses</u> 1998 May;50(5):435-49 Abstract
	22OD	Boulton AJ, et al., "Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy", <u>Diabetes Metab</u> 1998 Nov;24 Suppl 3:55-65 Abstract
	23OD	Tutuncu NB et al., "Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study", <u>Diabetes Care</u> , 1998 Nov;21(11):1915-8 Abstract
	24OD	van Dam PS, et al., "Diabetic peripheral neuropathy: international guidelines for prevention, diagnosis, and treatment (comment)", <u>Ned Tijdschr Geneesk</u> 2000 Feb 26;144(9):418-21 Abstract
	25OD	Zangaro GA et al., "Diabetic neuropathy: pathophysiology and prevention of foot ulcers" <u>Clin Nurse Spec</u> 1999 Mar;13(2):57-65; quiz 66-8. Abstract
	26OD	Boulton AJ, et al., "Diabetic Neuropathy", <u>Med Clin North Am</u> , 1998 Jul;82(4):909-29 Abstract
	27OD	Feldman EL, et al., "Pathogenesis of diabetic neuropathy" <u>Clin Neurosci</u> , 1997;4(6):365-70 Abstract
	28OD	Qian M, et al., "Glycochelates and the etiology of diabetic peripheral neuropathy" <u>Free Radic Biol Med</u> 2000 Feb 15;28(4):652-6 Abstract
	29OD	Galer BS, et al., "Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life", <u>Diabetes Res Clin Pract</u> 2000 Feb;47(2):123-8 Abstract
	30OD	Kaneto H, et al., "Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity" <u>Diabetes</u> 1999 Dec;48(12):2398-406 Abstract
	31OD	Simon-Schnass I, et al. "Nutrient Intake of 130 Type II Diabetics", Nutrisan®, Privat-institut für Ernährungswissenschaft Dr. Irene Simon-Schnass, Unterfeldstrasse 5a, D-82377 Penzberg
	32OD	DiSilvestro R., "Zinc Deficiency-Diabetes Link Explored", internet download May 31, 2000 at http://www1.rf.ohio-state.edu/pubrpt/mh/zinc.htm
	33OD	Chusid, R., "Vitamins and Diabetes", internet download Sept. 25, 2000 at http://ourworld.compuserve.com/homepages/rchusid.vdm.htm
	34OD	"Alternative Therapies for Diabetes" by National Diabetes Information Clearinghouse, May 1999.
	35OD	Salonen JT et al., "Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men" <u>BMJ</u> 1995 Oct 28;311(7013):1124-7 Abstract
	36OD	Fox GN et al., "Chromium picolinate supplementation for diabetes mellitus" <u>Fam Pract</u> 1998 Jan;46(1):83-6 Abstract
	37OD	Nutrition Dynamics Inc., "Glyco Control."
	38OD	Diabetic Polyneuropathy, "Pathophysiology", Volume 1, 1999, Medscape, Inc.
	39OD	Diabetic Polyneuropathy, "Future Therapies", Vol. 1, 1999, Medscape, Inc.
	40OD	Diabetic Polyneuropathy, "Neurologic Examination", Volume 1, 1999, Medscape, Inc.
	41OD	Diabetic Polyneuropathy, "Symptom History", Vol. 1, 1999, Medscape, Inc.
	42OD	Van Acker et al., "Structural Aspects of Antioxidant Activity of Flavonoids", <u>Free Radic Biol Med</u> 1996;20(3):331-42 Abstract

BEST AVAILABLE COPY

EXAMINER:

S. V. O

DATE CONSIDERED:

9/15/04



FORM TO-1449 Modified

List of Patents and Publications Cited by Applicant

Patent Trademark Office

documents have not been received

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	43OD	Tiukavkima, et al., "Dihydroquercetin - a new antioxidant and biologically active food additive", <u>Vopr Pitan</u> 1997;(6):12-5 Abstract
	44OD	Plumb, et al., "Antioxidant properties of flavonal glycosides from tea", <u>Redox Rep</u> 1999;4(1-2):13-6 Abstract
	45OD	Duke, et al., "Biological Activities of CURCUMINOIDS", <u>Phytochemical and Ethnobotanical Database</u> .
	46OD	Robak, et al., "Bioactivity of flavonoids", <u>Pol J Pharmacol</u> 1996 Nov-Dec;48(6):555-64 Abstract
	47OD	Bursel, et al., "Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?", <u>Diabetes Res Clin Pract</u> 1999 Sep; 45(2-3):169-82 Abstract
	48OD	Freedman, et al., "Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release", <u>Circulation</u> 2001 Jun 12;103(23):2792-8 Abstract
	49OD	Lin, et al., "Recent studies on the biofunctions and biotransformations of curcumin", <u>Biofactors</u> 2000;13(1-4):153-8 Abstract
	50OD	Duarte, et al., "Vasodilator effects of quercetin in isolated rat vascular smooth muscle", <u>Eur J Pharmacol</u> 1993 Aug 239:1-7 Abstract
	51OD	Giugliano, et al., "Oxidative stress and diabetic vascular complications", <u>Diabetes Care</u> 1996 Mar;19(3):257-67 Abstract
	52OD	Fukuoka, M. et al., "Novel pharmacological activity of a vitamin (novel pharmacological action of vitamin D)", <u>Medscape Medline abstract</u> , <u>Nippon Yakurigaku Zasshi</u> October 1997, 110 Suppl. 1:39P-43P Abstract
	53OD	Riaz S. et al., "A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats", <u>Medscape Medline Abstract</u> , <u>Diabetologia</u> November 1999, 42(11): 1308-1313. Abstract
	54OD	Okada, Y. et al (cont) <u>Chem. Pharm Bull (Tokyo)</u> Aug. 1995, 43(8): 1385-1387. Abstract
	55OD	Sports Medicine Articles" (online), 01 September 2000 (retrieved on 2002-01-10) Retrieved from the Internet http://www.rehabnet.com/Sports/Actinic%20Dermatitis.htm , p. 1-2
	56OD	
	57OD	
	58OD	
	59OD	
	60OD	
	61OD	
	62OD	
	63OD	

BEST AVAILABLE COPY

Document have not been Received

EXAMINER:

S. W. 6

DATE CONSIDERED:

9/15/04

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	1OD	Cunningham JJ, "The glucose/insulin system and vitamin C: implications in insulin-dependent diabetes mellitus", <u>J Am Coll Nutr</u> 1998 Apr;17(2):105-8 Abstract
	2OD	Crabbe MJ, et al., "Aldose reductase: a window to the treatment of diabetic complications?", <u>Prog Retin Eye Res</u> 1998 Jul;17(3):313-83 Abstract
	3OD	Fujita T, et al., "Inhibitory effects of perillosides A and C, and related monoterpene glucosides on aldose reductase and their structure-activity relationships", <u>Chem Pharm Bull (Tokyo)</u> 1995 Jun;43(6):920-6 Abstract
	4OD	Guillausseau PJ, Preventive treatment of diabetic microrangiopathy: blocking the pathogenic mechanisms", <u>Diabete Metab</u> , 1994;20(2 Pt 2):219-28 Abstract
	5OD	McAuliffe AV et al., "Administration of ascorbic acid and an aldose reductase inhibitor (tolrestat) in diabetes: effect on urinary albumin excretion" <u>Nephron</u> 1998 Nov;80(3):277-84 Abstract
	6OD	Eaton RP, et al., "A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes", <u>J Diabetes Complications</u> 1998 Jan-Feb;12(1):34-8 Abstract
	7OD	Rastelli G, et al. "Structural bases for the inhibition of aldose reductase by phenolic compounds", <u>Bioorg Med Chem</u> , 2000 May;8(5):1151-8 Abstract
	8OD	Costantino L, et al., "Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches" <u>Med Res Rev</u> , 1999 Jan;19(1):3-23 Abstract
	9OD	Hosotani H, et al., "Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats" <u>Curr Eye Res</u> 1996 Oct;15(10):1005-7 Abstract
	10OD	Haraguchi H et al., "Inhibition of aldose reductase by dihydroflavonols in Engelhardtia chrysolepis and effects on other enzymes", <u>Experimentia</u> , 1996 June 15;52 (6) 564-7 Abstract
	11OD	Ohguro N, et al., "Topical Aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients" <u>Br J Ophthalmol</u> , 1995 Dec;79(12):1074-7 Abstract
	12OD	Benstead TJ, et al., "Nerve microvessel changes in diabetes are prevented by aldose reductase inhibition", <u>Can J Neurol Sci</u> 1995 Aug;22(3):192-7 Abstract
	13OD	Okada Y, et al., "Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation" <u>Chem Pharm Bull (Tokyo)</u> 1995 Aug;43(8):1385-7 Abstract
	14OD	Costantino L, et al., "1-Benzopyran-4-one antioxidants as aldose reductase inhibitors", <u>J Med Chem</u> 1999 Jun 3;42(11):1881-93 Abstract
	15OD	Nishimura-Yabe C, "Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications" <u>Nippon Yakurigaku Zasshi</u> 1998 Mar;111(3):137-45 Abstract
	16OD	Tomlinson DR, et al., "Aldose reductase inhibitors and their potential for the treatment of diabetic complications" <u>Trends Pharmacol Sci</u> 1994 Aug;15(8):293-7 Abstract
	17OD	Airey M, et al., "Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy", <u>Cochrane Database Syst Rev</u> 2000;(2):CD002182 Abstract
	18OD	Maxwell SR, et al., "Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus", <u>Eur J Clin Invest</u> 1997 Jun;27(6):484-90 Abstract
	19OD	Himmerich S, et al., "Effect of Vitamins E and C on Nitric Oxide Production in Oxidized Low Density Lipoprotein Treated Human Aortic Endothelial Cells", <u>Academic Press</u> ; 2000, internet download at http://www.academicpress.com/www/journal/niox/9204.html
	20OD	Asahi K, et al., "Nitric Oxide Inhibits the Formation of Advanced Glycation End Products", <u>Kidney Int</u> 2000 Oct;58(4):1780-7

BEST AVAILABLE COPY

EXAMINER:

DATE CONSIDERED:

FORM PTO-1449 Modified

Filed: May 2, 2001

List of Patents and Publications Cited by Applicant

Group: 1617

U.S. Patent Trademark Office

Applicant: Rosenbloom

Docket No.: QUIG-1002US

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	21OD	McCarty MF, "Nitric oxide deficiency, leukocyte activation and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline" <u>Med Hypotheses</u> 1998 May;50(5):435-49 Abstract
	22OD	Boulton AJ, et al., "Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy", <u>Diabetes Metab</u> 1998 Nov;24 Suppl 3:55-65 Abstract
	23OD	Tutuncu NB et al., "Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study", <u>Diabetes Care</u> , 1998 Nov;21(11):1915-8 Abstract
	24OD	van Dam PS, et al., "Diabetic peripheral neuropathy: international guidelines for prevention, diagnosis, and treatment (comment)", <u>Ned Tijdschr Geneesk</u> 2000 Feb 26;144(9):418-21 Abstract
	25OD	Zangaro GA et al., "Diabetic neuropathy: pathophysiology and prevention of foot ulcers" <u>Clin Nurse Spec</u> 1999 Mar;13(2):57-65; quiz 66-8. Abstract
	26OD	Boulton AJ, et al., "Diabetic Neuropathy", <u>Med Clin North Am</u> , 1998 Jul;82(4):909-29 Abstract
	27OD	Feldman EL, et al., "Pathogenesis of diabetic neuropathy" <u>Clin Neurosci</u> , 1997;4(6):365-70 Abstract
	28OD	Qian M, et al., "Glycochelates and the etiology of diabetic peripheral neuropathy" <u>Free Radic Biol Med</u> 2000 Feb 15;28(4):652-6 Abstract
	29OD	Galer BS, et al., "Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life", <u>Diabetes Res Clin Pract</u> 2000 Feb;47(2):123-8 Abstract
	30OD	Kaneto H, et al., "Beneficial effects of antioxidants in diabetes: possible protection of pancreatic beta-cells against glucose toxicity" <u>Diabetes</u> 1999 Dec;48(12):2398-406 Abstract
	31OD	Simon-Schnass I., et al. "Nutrient Intake of 130 Type II Diabetics", Nutrisan®, Privat-institut für Ernährungswissenschaft Dr. Irene Simon-Schnass, Unterfeldstrasse 5a, D-82377 Penzberg
	32OD	DiSilvestro R., "Zinc Deficiency-Diabetes Link Explored", internet download May 31, 2000 at http://www1.rf.ohio-state.edu/pubrpt/mh/zinc.htm
	33OD	Chusid, R., "Vitamins and Diabetes", internet download Sept. 25, 2000 at http://ourworld.compuserve.com/homepages/rchusid.vdm.htm
	34OD	"Alternative Therapies for Diabetes" by National Diabetes Information Clearinghouse, May 1999.
	35OD	Salonen JT et al., "Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men" <u>BMJ</u> 1995 Oct 28;311(7013):1124-7 Abstract
	36OD	Fox GN et al., "Chromium picolinate supplementation for diabetes mellitus" <u>Fam Pract</u> 1998 Jan;46(1):83-6 Abstract
	37OD	Nutrition Dynamics Inc., "Glyco Control."
	38OD	Diabetic Polyneuropathy, "Pathophysiology", Volume 1, 1999, Medscape, Inc.
	39OD	Diabetic Polyneuropathy, "Future Therapies", Vol. 1, 1999, Medscape, Inc.
	40OD	Diabetic Polyneuropathy, "Neurologic Examination", Volume 1, 1999, Medscape, Inc.
	41OD	Diabetic Polyneuropathy, "Symptom History", Vol. 1, 1999, Medscape, Inc.
	42OD	Van Acker et al., "Structural Aspects of Antioxidant Activity of Flavonoids", <u>Free Radic Biol Med</u> 1996;20(3):331-42 Abstract

BEST AVAILABLE COPY

EXAMINER:

DATE CONSIDERED:

FORM PTO-1449 Modified

Filed: May 2, 2001

List of Patents and Publications Cited by Applicant

Group: 1617

U.S. Patent Trademark Office

Applicant: Rosenbloom

Docket No.: QUIG-1002US

Examiner Initial	Item No.	Other Documents (Including Author, Title, Date, Location and Pertinent Pages)
	43OD	Tiukavkima, et al., "Dihydroquercetin - a new antioxidant and biologically active food additive", <u>Vopr Pitan</u> 1997;(6):12-5 Abstract
	44OD	Plumb, et al., "Antioxidant properties of flavonol glycosides from tea", <u>Redox Rep</u> 1999;4(1-2):13-6 Abstract
	45OD	Duke, et al., "Biological Activities of CURCUMINOIDS", <u>Phytochemical and Ethnobotanical Database</u> .
	46OD	Robak, et al., "Bioactivity of flavonoids", <u>Pol J Pharmacol</u> 1996 Nov-Dec;48(6):555-64 Abstract
	47OD	Bursel, et al., "Can protein kinase C inhibition and vitamin E prevent the development of diabetic vascular complications?", <u>Diabetes Res Clin Pract</u> 1999 Sep; 45(2-3):169-82 Abstract
	48OD	Freedman, et al., "Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release", <u>Circulation</u> 2001 Jun 12;103(23):2792-8 Abstract
	49OD	Lin, et al., "Recent studies on the biofunctions and biotransformations of curcumin", <u>Biofactors</u> 2000;13(1-4):153-8 Abstract
	50OD	Duarte, et al., "Vasodilator effects of quercetin in isolated rat vascular smooth muscle", <u>Eur J Pharmacol</u> 1993 Aug 239:1-7 Abstract
	51OD	Giugliano, et al., "Oxidative stress and diabetic vascular complications", <u>Diabetes Care</u> 1996 Mar;19(3):257-67 Abstract
	52OD	Fukuoka, M. et al., "Novel pharmacological activity of a vitamin (novel pharmacological action of vitamin D)", <u>Medscape Medline abstract</u> , <u>Nippon Yakurigaku Zasshi</u> October 1997, 110 Suppl. 1:39P-43P Abstract
	53OD	Riaz S. et al., "A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats", <u>Medscape Medline Abstract</u> , <u>Diabetologia</u> November 1999, 42(11): 1308-1313. Abstract
	54OD	Okada, Y, et al (cont) <u>Chem. Pharm Bull (Tokyo)</u> Aug. 1995, 43(8): 1385-1387. Abstract
	55OD	<u>Sports Medicine Articles</u> (online), 01 September 2000 (retrieved on 2002-01-10) Retrieved from the Internet http://www.rehabnet.com/Sports/Actinic%20Dermatitis.htm , p. 1-2
	56OD	
	57OD	
	58OD	
	59OD	
	60OD	
	61OD	
	62OD	
	63OD	

BEST AVAILABLE COPY

EXAMINER:

DATE CONSIDERED:

BEST AVAILABLE COPY

✓
RECEIVED BY THE U.S. PATENT AND TRADEMARK OFFICE

Request For Continued Examination Transmittal,
Transmittal of Information Disclosure Statement; Form
PTO-1449; copies of cited references and check in the
amount of \$385.00

ROSENBLOOM

Applicant:

Serial No.: 09/847,121

Docket No. QUIG-1002US

Date Sent: April 14, 2004

KJD: cpm

Filed: 5/2/2001

